What is the most exciting, important, promising, all-around awesome stem cell biotech of 2014? Vote and tell us why in the comments.
The future is now. Or so goes the expression. For CIRM, it rings true today. Last year I blogged about what we might expect from the new CIRM that would evolve and take form in the future. I was particularly […]
I’ve added a fun and helpful new feature on the right side bar of the blog in the form of a stock ticker for some of the most widely held stem and cellular medicine companies. A sample screen shot is […]
Where do things stand with some players in the for-profit world of stem cell and cellular medicine companies? Here are a few brief news items with quick analysis. Mesoblast is dominating the news of late. Mesoblast reported good news from […]
Osiris, a cellular therapy biotech, recently received a so-called “untitled letter” from the FDA. The text of the letter seems on the whole negative in my opinion, while the company’s public reaction to the letter on the other hand could […]